Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ervogastat Phase 1b Study in Adults with NAFLD
NCT03513588Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ervogastat in non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Pfizer. Primary endpoint: Relative Change From Baseline in Whole Liver Fat at Day 15. Started Jun 2018; status: completed.
02
Drugs
ervogastat
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03513588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03513588.